New regulatory factor identified in bone formation


Credit: Mary Ann Liebert, Inc., publishers

New Rochelle, NY, March 11, 2019-Researchers report the identification of a novel transcription factor that helps regulate the differentiation of mesenchymal stem cells (MSCs) into bone in mice. Bone cell differentiation is still poorly understood, and MSCs offer a promising source of stem cells for regenerative medicine applications. The new transcription factor, called Osteoblast Inducer (ObI)-1, is described in an article published in Stem Cells and Development, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. Click here to read the full-text article free through April 11, 2019.

The article entitled “Identification of a Novel Transcription Factor Required for Osteogenic Differentiation of Mesenchymal Stem Cells” was coauthored by Francesca Querques and Anna DAgostino, CEINGE-Biotecnologie Avanzate (Naples, Italy), Università degli Studi di Napoli “Federico II” (Naples), and SEMM-European School for Molecular Medicine (Naples) and a team of researchers from these institutions and CRG-Centre for Genomic Regulation (Barcelona, Spain). The researchers identified ObI-1 in a screen of mouse MSCs and went on to show that it acts, at least in part, by stimulating the BMP signaling pathway, which controls the expression of Runx2.

“Lucio Pastore and colleagues report for the first time that a novel transcription factor they named Osteoblast Inducer-1 regulates osteogenic differentiation acting upstream of Runx2. In their elegant paper they used both knockdown and overexpression experiments in both a multipotent murine bone marrow cell line as well as primary murine mesenchymal stem cells,” says Editor-in-Chief Graham C. Parker, PhD, The Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI.


About the Journal

Stem Cells and Development is an authoritative peer-reviewed journal published 24 times per year in print and online. The Journal is dedicated to communication and objective analysis of developments in the biology, characteristics, and therapeutic utility of stem cells, especially those of the hematopoietic system. A complete table of contents and free sample issue may be viewed on the Stem Cells and Development website.

About the Publisher

Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Cellular Reprogramming, Tissue Engineering, and Human Gene Therapy. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers) website.

Media Contact
Kathryn Ryan
[email protected]

Original Source

Related Journal Article